Genotyping firm DxS to sell AstraZeneca technology:
This article was originally published in Clinica
Manchester, UK-based DxS, which provides genotyping services based on proprietary PCR-based technology, and BTG, an international group that specialises in developing technologies for licensing, are to commercialise a system owned by AstraZeneca. Called ARMS (Amplification Refractory Mutation System), it can be used to detect gene mutations and single nucleotide polymorphisms, and will be pitched to the diagnostic and research markets. For instance, it could be used to predict which patients will respond well to a medicine.